Abstract CT290: Trial in progress: Evaluation of the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of 177Lu-NeoB in patients with advanced solid tumors expressing gastrin-releasing peptide receptor (GRPR)
Year: 2024
Type: conference-abstract
Source: Cancer Research
Institutions: Oregon Health & Science University, Stanford Medicine, Erasmus MC, University of Cambridge, City Of Hope National Medical Center, City of Hope, Inserm, Laboratoire Radiopharmaceutiques Biocliniques, Université Grenoble Alpes, Novartis (Switzerland), Novartis (China), Johns Hopkins University, Johns Hopkins Medicine
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4393983545